April 17, 2018
News & Publications
Press Releases
April 10, 2018
H3 Biomedicine to Present at 2018 American Association for Cancer Research Annual Meeting
Presentations highlight leadership in RNA splicing, a strategic focus area of the H3 cancer genomics product engine Read More »
April 3, 2018
H3 Biomedicine Publishes Comprehensive Genomic Landscape Analysis in Cell Reports Revealing Breadth, Frequency and Potential Disease-Driving Significance of Somatic Mutations in RNA Splicing Factor Genes in Multiple Types of Cancer
Novel findings underscore promise of H3 Biomedicine’s first-in-class splicing factor modulator H3B-8800 currently in Phase 1 clinical trial for patients… Read More »
March 19, 2018
H3 Biomedicine to Present at the BioCentury Annual Future Leaders in the Biotech Industry Conference
Read More »
March 6, 2018
H3 Biomedicine to Present at the Cowen Annual Health Care Conference
Read More »
February 20, 2018
H3 Biomedicine Preclinical Proof-of-Concept Data on First-in-Class Spliceosome-Modulator Therapy for Genomically Identified Patients with Hematological Cancers Published in Nature Medicine
H3B-8800 is first known investigational therapy to target RNA splicing factor mutations, highly prevalent in many hematologic cancers Initial data… Read More »In the Media
BioPharm Insight
H3 Biomedicine in active discussions for co-developing its cancer genomics programs – CEO
H3 Biomedicine is in talks with pharma companies to co-develop one or more of its Phase I drugs that are… Read More »
Boston Business Journal
H3 Biomedicine to Begin Trials of First-Ever Gene-Splicing Cancer Drug
Kendall Square-based cancer biotech H3 Biomedicine, created five years ago by Japanese drug firm Eisai, will bring its first drug… Read More »
PharmaVOICE
H3 Biomedicine’s Dr. Lihua Yu Honored in PharmaVOICE 100
In her position as VP, data science and information technology, at H3 Biomedicine, Lihua Yu, Ph.D., is driving the expanded… Read More »
Boston Business Journal
Foundation Medicine, H3 Biomedicine Partner to Develop Cancer Drugs
A partnership announced today between two Cambridge companies, Foundation Medicine (Nasdaq: FMI) and H3 Biomedicine, is further evidence of the… Read More »Scientific Publications
Cell Report | October 22, 2015
Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point
Recurrent mutations in the spliceosome are observed in several human cancers, but their functional and therapeutic significance remains elusive. SF3B1,… Read More »
Cancer Cell | May 11, 2015
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition
Mutations affecting spliceosomal proteins are the most common mutations in patients with myelodysplastic syndromes (MDS), but their role in MDS… Read More »
H3 Biomedicine | December 8, 2014
Cancer-Associated Mutations in SF3B1 Exhibit Neomorphic Splicing Activity and Block Erythroid Differentiation
Poster Presentation at the 2014 Meeting of the American Society of Hematology on Monday, December 8, 2014. Read More »
ASC Publications | October 26, 2014
Total Synthesis of 6-Deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 Cancer Cell Line
A total synthesis of the natural product 6-deoxypladienolide D (1) has been achieved. Two noteworthy attributes of the synthesis are… Read More »Media Inquiries
For all media interested in speaking to members of H3 Biomedicine’s executive/scientific team, or receiving further information about the company or pipeline, please forward your request to Liz Melone.
